SOX2 and carcinoma: The customized development of iPeps derived from oncogenic TFs that are overexpressed in aggressive and chemoresistant carcinomas, such as SOX2, can selectively target specific tumors overexpressing these TFs thereby sensitizing these chemoresistant carcinomas to chemotherapy drugs.